Pazopanib In Uterine Sarcoma (Uts): Review Of Two European Organisation For Research And Treatment Of Cancer (Eortc) And Gsk Clinical Trials 62043 And 62072 On Pazopanib For Soft Tissue Sarcoma (Sts).

10579 Background: Pazopanib has been introduced recently in the treatment for patients with advanced STS. Multiple chemotherapies have been investigated for the treatment of advanced and recurrent UtS, but most of them result in only moderate response rates (RR) and duration. Methods: In this retrospective analysis we investigated the outcome of UtS pts treated with pazopanib in the two EORTC clinical trials, the phase II 62043 (n= 142) and the phase III trial 62072 Palette study (n= 246). Results: Forty-four pts with a UtS were treated with pazopanib. Histology was leiomyosarcoma (89%) and undifferentiated UtS (3%), 84% had histological grade 3 disease. Median age was 55 years (range 33-79 ; 16% u003e 70y), 41% had performance status (PS) 0, 59% PS 1. At start of pazopanib 73% had lung metastases, 27% bone metastases, 25% liver metastases, 39% other metastases, and 14% had local recurrence. Most pts (83%) stopped pazopanib due to progressive disease, 14% due to toxicity. 28/44 pts (64%) reported a grade 3-...